Navigation Links
Varian Medical Systems Announces Net Orders Growth Estimates for the First Quarter of Fiscal Year 2009
Date:1/12/2009

ce on sole or limited-source suppliers; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the company's ability to maintain or increase operating margins; the impact of competitive products and pricing; the effect of changes in accounting principles; the company's ability to meet Food and Drug Administration and other regulatory requirements for product clearances or to comply with Food and Drug Administration and other regulatory regulations or procedures; the ability to make strategic acquisitions and to successfully integrate the acquired operations into the company's business; the possibility that litigation, including but not limited to litigation matters involving material product liability claims, could harm future revenues or require the company to pay uninsured claims; the effect of environmental claims and expenses; the company's ability to protect the company's intellectual property; the impact of managed care initiatives, other health care reforms and/or third-party reimbursement levels; the potential loss of key distributors or key personnel; consolidation in the X-ray tubes market; the risk of operations interruptions due to terrorism, disease or other events beyond the company's control; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

     FOR INFORMATION CONTACT:
     Elisha Finney (650) 424-6803
     elisha.finney@varian.com

     Spencer Sias (650) 424-5782
     spencer.sias@varian.com

'/>"/>
SOURCE Varian Medical Systems
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Gene Variant May Hike Womens Risk of Alzheimers
2. Treadmill Desks Combat Obesity Linked to Higher Rates of Ovarian Cancer
3. Biologist finds plant polymerases IV and V are really variants of Polymerase II
4. Obesity Linked to Ovarian Cancer
5. Study links obesity to elevated risk of ovarian cancer
6. Minimizing obesitys impact on ovarian cancer survival
7. Gene Variant Tied to Smokers Risk of Lung Cancer
8. Low Levels of 2 Enzymes in Ovarian Cancer Cells Shortened Survival
9. Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test
10. Stopping ovarian cancer by blocking proteins coded by notorious gene
11. Blocking Oncogene Can Stop Spread of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... 700 smiling little faces this holiday that might not ... monetary donations was given to the various charities as ... incur through the year. Some of the charities chosen ... , Shrine's Children's Hospitals, Toys for Tots and Crisis ...
(Date:12/24/2014)... Rosa, CA (PRWEB) December 24, 2014 New ... particularly susceptible to hearing loss related depression (March 6, 2014, ... associated with gradual hearing loss (about 50 percent according to ... extremely positive effect on how a person feels and relates ... report that overall improvements are also made by way of:, ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. Stivarga is a drug which is used in ... is orally administered and is also prescribed to patients ... which is FDA approved is a multi-kinase inhibitor and ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... intra-aortic balloon pumps prior to angioplasty in patients with ... of heart muscle damage, a condition referred to as ... Duke University Medical Center researchers. The findings ... the American Medical Association ( JAMA ), and ...
... , MONDAY, Aug. 29 (HealthDay News) -- Although older ... may not be making good decisions about their coverage, ... -- particularly those with impaired brain function -- can ... plans available to them, preventing them from finding the ...
... , MONDAY, Aug. 29 (HealthDay News) -- The width ... performs, according to a new study. Researchers compared the ... their companies, financial performance. The study included only men because ... behavior applies only to men. The firms of CEOs ...
... agree that financial constraints and an aging population will require ... find that pushing back the eligibility age could be a ... most. The consequences both positive and negative of ... presented in the latest installment of the Public Policy & ...
... Caution is required when deciding whether to stop life support ... Researchers examined death rates after life support was ... brain injury in six trauma centers in the Canadian provinces ... the patients died in hospital, but the rate varied from ...
... EMPHASIS-HF study showed significant reductions in death and hospitalization ... failure (CHF) and mild symptoms treated with eplerenone in ... and standard therapy. Commenting on the findings presented ... Cardiology Congress (ESC) Hot Line Session on 29th August ...
Cached Medicine News:Health News:Study shows balloon pump use prior to angioplasty does not reduce heart muscle damage 2Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 2Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 3Health News:Aging authorities differ on tweaks to Social Security's benefit structure 2Health News:Use Caution in Ending Life Support for Brain-Injured, Experts Say 2Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 2Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 3
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. 23, ... International plc (NASDAQ: ENDP ) (TSX: ENL), ... ) announced today that they have submitted a New ... the U.S. Food and Drug Administration (FDA).  Buprenorphine HCl ... pain severe enough to require daily, around-the-clock, long-term opioid ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Study Suggests That Ekkyo,s New Approach of LASH ... can Drastically Improve Scar Healing Physiology, MARSEILLES, ... Technology) a photomedicine company, which develops first-in-class,laser-based systems ... publication of a scientific article in Lasers in ...
... M.D., president of SPRI,Clinical Trials, will be a featured ... Group Investor Seminar -- Management,s Guide to,Wall Street. The ... Midtown,Loft & Terrace, 267 Fifth Avenue in New York. ... and small and mid-cap life science companies to gain,better ...
Cached Medicine Technology:Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
VascoStim B 2/5F is a bipolar temporary pacing lead with a balloon. It can be placed easily by the resistance of the inflated balloon in the blood flow....
Medicine Products: